Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Impact · against what's priced in

Praxis Precision Medicines is moving toward commercialization with a confirmed FDA path to file an NDA for relutrigine in early 2026. This provides a concrete regulatory timeline backed by Phase 2 EMBOLD efficacy data, reducing the risk profile for the company's lead candidate.

PRAX+0.70

No priced-in read yet